$PCYN
PROCYON CORP Stock $pcyn

$pcyn Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-K Financial Statement

#000143774924032155 Filed on October 25, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2024
Revenue		$1.413M	$4.984M
YoY Change		17.51%	6.35%
Cost Of Revenue		$308.2K	$1.093M
YoY Change		16.23%	-2.16%
Gross Profit		$1.105M	$3.891M
YoY Change		17.87%	9.02%
Gross Profit Margin		78.18%	78.07%
Selling, General & Admin		$1.096M	$2.038M
YoY Change		16.53%	12.78%
% of Gross Profit		99.2%	52.37%
Research & Development			$30.10K
YoY Change			-1.63%
% of Gross Profit			0.77%
Depreciation & Amortization		$20.74K	$81.70K
YoY Change		7.24%	54.69%
% of Gross Profit		1.88%	2.1%
Operating Expenses		$1.096M	$2.068M
YoY Change		16.53%	12.54%
Operating Profit		$8.890K	-$231.7K
YoY Change		-382.22%	137.94%
Interest Expense		$7.190K	$24.64K
YoY Change		47.64%	108.46%
% of Operating Profit		80.88%
Other Income/Expense, Net		$9.150K	$60.42K
YoY Change		3.74%	88.78%
Pretax Income		$25.24K	-$171.3K
YoY Change		139.7%	162.0%
Income Tax		-$12.74K	$169.9K
% Of Pretax Income		-50.48%
Net Earnings		$37.98K	-$341.1K
YoY Change		406.96%	578.95%
Net Earnings / Revenue		2.69%	-6.84%
Basic Earnings Per Share			-$0.04
Diluted Earnings Per Share		$0.01	-$0.04
COMMON SHARES
Basic Shares Outstanding	8.120M	8.108M	8.120M
Diluted Shares Outstanding			8.120M

Balance Sheet

Concept	2024 Q2	2024
SHORT-TERM ASSETS
Cash & Short-Term Investments	$908.8K	$908.8K
YoY Change	-10.35%	-10.35%
Cash & Equivalents	$326.1K
Short-Term Investments	$582.7K	$582.7K
Other Short-Term Assets	$434.2K	$434.2K
YoY Change	45.46%	45.46%
Inventory	$510.0K	$510.0K
Prepaid Expenses
Receivables	$512.9K	$512.9K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$2.366M	$2.366M
YoY Change	5.73%	5.73%
LONG-TERM ASSETS
Property, Plant & Equipment	$262.0K	$600.2K
YoY Change	-6.76%	-25.74%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$221.4K	$221.4K
YoY Change	-55.81%	-55.81%
Total Long-Term Assets	$838.5K	$838.5K
YoY Change	-36.77%	-36.77%
TOTAL ASSETS
Total Short-Term Assets	$2.366M	$2.366M
Total Long-Term Assets	$838.5K	$838.5K
Total Assets	$3.204M	$3.204M
YoY Change	-10.08%	-10.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$160.9K	$160.9K
YoY Change	-8.07%	-8.08%
Accrued Expenses	$608.3K	$608.3K
YoY Change	34.86%	34.86%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$769.2K	$769.2K
YoY Change	22.86%	22.86%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$139.2K	$139.2K
YoY Change	-56.48%	-56.48%
Total Long-Term Liabilities	$147.9K	$139.2K
YoY Change	-53.77%	-56.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$769.2K	$769.2K
Total Long-Term Liabilities	$147.9K	$139.2K
Total Liabilities	$917.1K	$917.1K
YoY Change	-3.05%	-3.05%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.331M
YoY Change	17.15%
Common Stock	$4.462M
YoY Change	0.39%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.287M	$2.287M
YoY Change
Total Liabilities & Shareholders Equity	$3.204M	$3.204M
YoY Change	-10.08%	-10.08%

Cashflow Statement

Concept	2024 Q2	2024
OPERATING ACTIVITIES
Net Income	$37.98K	-$341.1K
YoY Change	406.96%	578.95%
Depreciation, Depletion And Amortization	$20.74K	$81.70K
YoY Change	7.24%	54.69%
Cash From Operating Activities	$2.640K	-$61.25K
YoY Change	-98.33%	-142.11%
INVESTING ACTIVITIES
Capital Expenditures	$1.620K	$63.91K
YoY Change	-98.95%	-64.52%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Cash From Investing Activities	-$1.620K	-$63.91K
YoY Change	-98.93%	-85.94%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	$0.00
YoY Change	-100.0%
NET CHANGE
Cash From Operating Activities	2.640K	-$61.25K
Cash From Investing Activities	-1.620K	-$63.91K
Cash From Financing Activities	0.000	$0.00
Net Change In Cash	1.020K	-$125.2K
YoY Change	-99.2%	-59.51%
FREE CASH FLOW
Cash From Operating Activities	$2.640K	-$61.25K
Capital Expenditures	$1.620K	$63.91K
Free Cash Flow	$1.020K	-$125.2K
YoY Change	-72.21%	260.99%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-341140	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-50245	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	37976	usd
CY2024	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	-28178	usd
CY2023	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	16710	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-20078	usd
CY2024	dei	Document Type DocumentType	10-K
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Security12g Title Security12gTitle	Common Stock
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Public Float EntityPublicFloat	1018330	usd
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8120388
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
CY2024	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	59-3280822
CY2024	dei	Entity Address Address Line1 EntityAddressAddressLine1	164 Douglas Rd
CY2024	dei	Entity Address City Or Town EntityAddressCityOrTown	Oldsmar
CY2024	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2024	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	34677
CY2024	dei	City Area Code CityAreaCode	727
CY2024	dei	Local Phone Number LocalPhoneNumber	447-2998
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	2594575	usd
CY2024	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-1214	usd
CY2024	pcyn	Other Income And Gain Loss On Extinguishment Of Debt OtherIncomeAndGainLossOnExtinguishmentOfDebt	974	usd
CY2023	pcyn	Other Income And Gain Loss On Extinguishment Of Debt OtherIncomeAndGainLossOnExtinguishmentOfDebt	0	usd
CY2023	us-gaap	Rental Income Nonoperating RentalIncomeNonoperating	20191	usd
CY2024	us-gaap	Rental Income Nonoperating RentalIncomeNonoperating	36022	usd
CY2024	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	60423	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	32007	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-65374	usd
CY2024	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2024	dei	Amendment Flag AmendmentFlag	false
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0000812306
CY2024	pcyn	Percentage Of Discount On Bill Payment Within Ten Days To Physicians PercentageOfDiscountOnBillPaymentWithinTenDaysToPhysicians	0.02	pure
CY2024	pcyn	Percentage Of Discount On Bill Payment Within Ten Days To Pharmaceutical Distributors And Drug Stores PercentageOfDiscountOnBillPaymentWithinTenDaysToPharmaceuticalDistributorsAndDrugStores	0.02	pure
CY2024	pcyn	Number Of Wholly Owned Subsidiaries NumberOfWhollyOwnedSubsidiaries	2	pure
CY2023Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2024Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2024	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024	dei	Document Transition Report DocumentTransitionReport	false
CY2024	dei	Entity File Number EntityFileNumber	0-17449
CY2024	dei	Entity Registrant Name EntityRegistrantName	PROCYON CORPORATION
CY2024	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	CO
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Auditor Firm AuditorFirmId	232
CY2024	dei	Auditor Name AuditorName	Ferlita, Walsh, Gonzalez & Rodriguez, P.A.
CY2024	dei	Auditor Location AuditorLocation	Tampa, Florida
CY2024Q2	us-gaap	Cash Cash	326143	usd
CY2023Q2	us-gaap	Cash Cash	451306	usd
CY2024Q2	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	582677	usd
CY2023Q2	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	562472	usd
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	15000	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	11625	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	512909	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	493953	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	510006	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	431405	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	434150	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	298469	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	2365885	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	2237605	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	262020	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	281023	usd
CY2024Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	4665	usd
CY2023Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	9220	usd
CY2024Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	216701	usd
CY2023Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	330513	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	17000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	17000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	338141	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	527170	usd
CY2024Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	0	usd
CY2023Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	161180	usd
CY2024Q2	pcyn	Assets Noncurrent Excluding Property Plant And Equipment AssetsNoncurrentExcludingPropertyPlantAndEquipment	576507	usd
CY2023Q2	pcyn	Assets Noncurrent Excluding Property Plant And Equipment AssetsNoncurrentExcludingPropertyPlantAndEquipment	1045083	usd
CY2024Q2	us-gaap	Assets Assets	3204412	usd
CY2023Q2	us-gaap	Assets Assets	3563711	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	160922	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	175057	usd
CY2024Q2	pcyn	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	427647	usd
CY2023Q2	pcyn	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	277498	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	180665	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	173565	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	769234	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	626120	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	139211	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	319882	usd
CY2024Q2	pcyn	Deferred Tax Liabilities Valuation Allowance DeferredTaxLiabilitiesValuationAllowance	209003	usd
CY2024Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	8677	usd
CY2023Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	0	usd
CY2024Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	147888	usd
CY2023Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	319882	usd
CY2024Q2	us-gaap	Liabilities Liabilities	917122	usd
CY2023Q2	us-gaap	Liabilities Liabilities	946002	usd
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	usd
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	usd
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8120388
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8120388
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8087388
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8087388
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	4462166	usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	4444766	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	41085	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	35564	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2330621	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1989481	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	2287290	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	2617709	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3204412	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3563711	usd
CY2024	us-gaap	Revenues Revenues	4984433	usd
CY2023	us-gaap	Revenues Revenues	4686659	usd
CY2024	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1092998	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1117072	usd
CY2024	us-gaap	Gross Profit GrossProfit	3891435	usd
CY2023	us-gaap	Gross Profit GrossProfit	3569587	usd
CY2024	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	2085209	usd
CY2023	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	1859980	usd
CY2024	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2037931	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1806988	usd
CY2024	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	4123140	usd
CY2023	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	3666968	usd
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-231705	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-97381	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	usd
CY2024	us-gaap	Investment Income Interest InvestmentIncomeInterest	24641	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	11816	usd
CY2024	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	0	usd
CY2023	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	0	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-171282	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	169858	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-15129	usd
CY2024	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-312962	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-66955	usd
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8120388
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8087388
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8120388
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8087388
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	2617709	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	10721	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-33855	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-242473	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	2352102	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-102788	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	2249314	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	2287290	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	2667954	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-8187	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	2659767	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2639689	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-29471	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	2610218	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	7491	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	2617709	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-341140	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-50245	usd
CY2024	us-gaap	Depreciation Depreciation	81701	usd
CY2023	us-gaap	Depreciation Depreciation	52817	usd
CY2024	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	3375	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-1944	usd
CY2024	pcyn	Operating Lease Right Of Use Asset Amortization Expense Reversal OperatingLeaseRightOfUseAssetAmortizationExpenseReversal	189029	usd
CY2023	pcyn	Operating Lease Right Of Use Asset Amortization Expense Reversal OperatingLeaseRightOfUseAssetAmortizationExpenseReversal	178985	usd
CY2024	pcyn	Accrued Interest On Certificates Of Deposit AccruedInterestOnCertificatesOfDeposit	20205	usd
CY2023	pcyn	Accrued Interest On Certificates Of Deposit AccruedInterestOnCertificatesOfDeposit	6949	usd
CY2024	pcyn	Deferred Income Tax Expense Benefit Gross DeferredIncomeTaxExpenseBenefitGross	-39146	usd
CY2023	pcyn	Deferred Income Tax Expense Benefit Gross DeferredIncomeTaxExpenseBenefitGross	16831	usd
CY2024	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-209003	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	31960	usd
CY2024	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	-1214	usd
CY2023	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	-0	usd
CY2024	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	22331	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	84924	usd
CY2024	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-4555	usd
CY2023	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-3091	usd
CY2024	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-35211	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-181957	usd
CY2024	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	135681	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-76348	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-14135	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3026	usd
CY2024	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	160870	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-25103	usd
CY2024	pcyn	Operating Lease Principal Payments OperatingLeasePrincipalPayments	173571	usd
CY2023	pcyn	Operating Lease Principal Payments OperatingLeasePrincipalPayments	160412	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-61251	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	145466	usd
CY2024	pcyn	Payments For Purchases Of Cd PaymentsForPurchasesOfCD	-0	usd
CY2023	pcyn	Payments For Purchases Of Cd PaymentsForPurchasesOfCD	400000	usd
CY2024	pcyn	Payments For Redemption Of Certificates Of Deposit PaymentsForRedemptionOfCertificatesOfDeposit	-0	usd
CY2023	pcyn	Payments For Redemption Of Certificates Of Deposit PaymentsForRedemptionOfCertificatesOfDeposit	-125582	usd
CY2024	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	63912	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	180138	usd
CY2024	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-63912	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-454556	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-125163	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-309090	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	451306	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	760396	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	326143	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	451306	usd
CY2024	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2024	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2024	pcyn	Accrued Expenses Settled For Issuance Of Equity AccruedExpensesSettledForIssuanceOfEquity	10721	usd
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Use of Estimates</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2024	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Concentration of Credit Risk</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company maintains its cash at various financial institutions. All accounts are fully insured by the Federal Deposit Insurance Corporation, up to $250,000 per Company. At June 30, 2024 and 2023, our uninsured cash balance was $105,107 and $0 respectively.</p>
CY2024Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	105107	usd
CY2023Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	0	usd
CY2024	pcyn	Term Of Sale For Pharmaceutical Distributors And Drug Stores TermOfSaleForPharmaceuticalDistributorsAndDrugStores	P30D
CY2024	pcyn	Standard Payment Term To Physicians StandardPaymentTermToPhysicians	P30D
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	15000	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	11600	usd
CY2024Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	209003	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	0	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	115000
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.26
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	115000
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.26
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	25432
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.24
CY2024	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	140432
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.25
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	115000
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.26
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	140432
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.25
CY2024Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	629750	usd
CY2023Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	576548	usd
CY2024Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	96957	usd
CY2023Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	185370	usd
CY2024Q2	us-gaap	Inventory Gross InventoryGross	726707	usd
CY2023Q2	us-gaap	Inventory Gross InventoryGross	761918	usd
CY2024Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	216701	usd
CY2023Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	330513	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	558703	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	296683	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	262020	usd
CY2024	us-gaap	Depreciation Depreciation	81701	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	606883	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	325860	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	281023	usd
CY2023	us-gaap	Depreciation Depreciation	52817	usd
CY2024Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	146847	usd
CY2023Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	70298	usd
CY2024Q2	us-gaap	Accrued Vacation Current AccruedVacationCurrent	50279	usd
CY2023Q2	us-gaap	Accrued Vacation Current AccruedVacationCurrent	33820	usd
CY2024Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	59171	usd
CY2023Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	48793	usd
CY2024Q2	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	47470	usd
CY2023Q2	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	24387	usd
CY2024Q2	pcyn	Accrued Lease Liability AccruedLeaseLiability	106842	usd
CY2023Q2	pcyn	Accrued Lease Liability AccruedLeaseLiability	92856	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	17038	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	7344	usd
CY2024Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	427647	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	277498	usd
CY2021Q2	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	250000	usd
CY2024Q2	us-gaap	Line Of Credit LineOfCredit	0	usd
CY2024	us-gaap	Interest Expense Debt InterestExpenseDebt	0	usd
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	0	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	188353	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	141062	usd
CY2024	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7705	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10721	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-341140	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-50245	usd
CY2024	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	-28178	usd
CY2023	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	16710	usd
CY2024	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-312962	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-66955	usd
CY2024	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-312962	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-66955	usd
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8120388
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8087388
CY2024	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0
CY2023	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0
CY2024	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	0
CY2023	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	0
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8120388
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8087388
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2024Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	825000	usd
CY2024	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2024	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2024	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2024	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-140737	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	12535	usd
CY2024	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-29121	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	2594	usd
CY2024	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	-169858	usd
CY2023	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	15129	usd
CY2024Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	209003	usd
CY2024Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	8340	usd
CY2024Q2	pcyn	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	81073	usd
CY2024Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Compensated Absences DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences	12743	usd
CY2024Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses	12031	usd
CY2024Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4220	usd
CY2024Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	327410	usd
CY2024Q2	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	85702	usd
CY2024Q2	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	41382	usd
CY2024Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	127084	usd
CY2024Q2	pcyn	Deferred Tax Assets Liabilities Gross DeferredTaxAssetsLiabilitiesGross	200326	usd
CY2024Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	209003	usd
CY2024Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	8677	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	-0	usd
CY2024Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	209003	usd
CY2024	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-209003	usd
CY2024	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.2535	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.2535	pure
CY2024	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	35969	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	13767	usd
CY2024	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	7442	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	2848	usd
CY2024	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	-4640	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	-1246	usd
CY2024	pcyn	Effective Income Tax Rate Reconciliation Loss Carryforward Amount EffectiveIncomeTaxRateReconciliationLossCarryforwardAmount	-374	usd
CY2023	pcyn	Effective Income Tax Rate Reconciliation Loss Carryforward Amount EffectiveIncomeTaxRateReconciliationLossCarryforwardAmount	32200	usd
CY2024	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-209003	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	31960	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	169858	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-15129	usd
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30100	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30600	usd
CY2024Q2	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.0425	pure
CY2024	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	979744	usd
CY2024	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	641603	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	338141	usd
CY2015Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	979744	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	659868	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	319876	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	180665	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	139211	usd
CY2024	us-gaap	Variable Lease Cost VariableLeaseCost	202270	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	202270	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y8M26D
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0328	pure
CY2024	us-gaap	Sublease Income SubleaseIncome	36022	usd
CY2023	us-gaap	Sublease Income SubleaseIncome	19908	usd
CY2024Q2	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	14930	usd
CY2024Q2	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	0	usd
CY2024Q2	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	0	usd
CY2024Q2	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	0	usd
CY2024Q2	us-gaap	Lessor Operating Lease Payments To Be Received Five Years LessorOperatingLeasePaymentsToBeReceivedFiveYears	0	usd
CY2024Q2	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	14930	usd

Files In Submission

Name	View Source	Status
0001437749-24-032155-index-headers.html	Edgar Link	pending
0001437749-24-032155-index.html	Edgar Link	pending
0001437749-24-032155.txt	Edgar Link	pending
0001437749-24-032155-xbrl.zip	Edgar Link	pending
ex_737011.htm	Edgar Link	pending
ex_737012.htm	Edgar Link	pending
ex_737013.htm	Edgar Link	pending
ex_737071.htm	Edgar Link	pending
ex_737072.htm	Edgar Link	pending
ex_737073.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pcyn-20240630.xsd	Edgar Link	pending
pcyn20240630_10k.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
pcyn-20240630_pre.xml	Edgar Link	unprocessable
pcyn20240630_10k_htm.xml	Edgar Link	completed
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
pcyn-20240630_def.xml	Edgar Link	unprocessable
pcyn-20240630_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
pcyn-20240630_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PCYN
PROCYON CORP Stock $pcyn

2024 Q3 Form 10-K Financial Statement

#000143774924032155 Filed on October 25, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCYN PROCYON CORP Stock $pcyn

2024 Q3 Form 10-K Financial Statement

#000143774924032155 Filed on October 25, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCYN
PROCYON CORP Stock $pcyn